News

Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease

Dr Alex Gibson, Business Development Officer at Cytox discusses in MedNous how to predict a person’s genetic risk of developing Alzheimer's using Polygenic Risk Scores. First application is identifying patients most suitable to enter clinica...

Rinicare receives funding support from Innovate UK

Rinicare and The University Hospitals of Morecambe Bay NHS Trust are delighted to announce that they have received funding support from Innovate UK to proceed with a joint research project that will collect real-life evidence of the benefits of Ri...

Catapult invests in Biohabit through the GM&C Life Sciences Fund

Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund. Biohabit are developing a salivary test for diagnosis of heart failure, that hopes to replace the need for...

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis. The IND is a crucial milestone in t...

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial...

From our portfolio

Pronec

Pharmaceuticals

viewview our portfolio

Our Team

Dr David Whitcombe

view complete team

Contact us

Alderley Park
Alderley Edge
Cheshire
SK10 4TG

Tel: 01625 344300

email